MiNK Therapeutics stockholders approve 1-for-10 reverse stock split effective Jan 28

MiNK Therapeutics, Inc.

Special meeting held Jan 17, 2025; 27,582,512 shares voted (quorum).
Proposal approved with 26,500,274 For, 1,026,255 Against, 56,013 Abstain.
Reverse split ratio 1-for-10, effective 12:01 a.m. ET on Jan 28, 2025.
Post-split shares trade under new CUSIP 603693 201 on Nasdaq.
39,630,402 shares outstanding pre-split as of record date Dec 16, 2024.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

MiNK Therapeutics, Inc.: Filed Certificate of Amendment to effect a 1-for-10 reverse stock split of common stock (effective 2025-01-28).

Change: charter amendment
Effective: 2025-01-28

Exact text from the filing

On January 17, 2025, MiNK Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.00001 (the “Common Stock”) at a ratio of 1-for-10 (the “Reverse Stock Split”).

View on SEC.gov

Browse all governance changes →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-009595

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.